Derek Maetzold Sells 817 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 817 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $37.99, for a total transaction of $31,037.83. Following the transaction, the insider owned 83,698 shares in the company, valued at $3,179,687.02. The trade was a 0.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Castle Biosciences Trading Down 7.3%

Shares of CSTL traded down $2.56 during mid-day trading on Thursday, reaching $32.40. The company’s stock had a trading volume of 763,751 shares, compared to its average volume of 405,892. Castle Biosciences, Inc. has a 52 week low of $14.59 and a 52 week high of $44.28. The stock has a market cap of $945.76 million, a PE ratio of -72.00 and a beta of 1.06. The company’s fifty day moving average price is $39.67 and its two-hundred day moving average price is $29.50. The company has a current ratio of 6.47, a quick ratio of 6.31 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The business had revenue of $80.55 million during the quarter, compared to the consensus estimate of $71.06 million. On average, analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on CSTL shares. Guggenheim lifted their price target on Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Weiss Ratings restated a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. Zacks Research upgraded shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday. Canaccord Genuity Group increased their price target on shares of Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Finally, Robert W. Baird raised their target price on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $47.14.

Institutional Investors Weigh In On Castle Biosciences

Large investors have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC bought a new stake in Castle Biosciences during the 3rd quarter worth approximately $16,105,000. Braidwell LP increased its holdings in shares of Castle Biosciences by 125.3% in the 2nd quarter. Braidwell LP now owns 822,735 shares of the company’s stock worth $16,800,000 after buying an additional 457,488 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new position in shares of Castle Biosciences during the 3rd quarter valued at approximately $9,108,000. Millennium Management LLC grew its holdings in Castle Biosciences by 34.2% during the 3rd quarter. Millennium Management LLC now owns 575,089 shares of the company’s stock valued at $13,095,000 after purchasing an additional 146,692 shares during the last quarter. Finally, Bridgeway Capital Management LLC grew its position in Castle Biosciences by 334.8% in the 3rd quarter. Bridgeway Capital Management LLC now owns 177,180 shares of the company’s stock valued at $4,034,000 after acquiring an additional 136,430 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.